

SAMPLE — NOT LEGAL ADVICE. This response letter was generated automatically from publicly available analysis. It has NOT been reviewed by a licensed attorney and SHOULD NOT BE SENT to any party without substantial review and customization by qualified patent counsel. Use as a starting point only.

[Your Name]

[Your Title]

[Your Company]

[Street Address, City, State ZIP]

May 14, 2026

[Opposing Counsel Name]

[Firm Name]

[Address]

Re: U.S. Patent No. 8685998 — Response to Assertion of Infringement

Dear Counsel,

We acknowledge receipt of your correspondence asserting infringement of U.S. Patent No. 8685998 (the "8685998 Patent"). After preliminary review, we have substantial concerns about the validity, enforceability, and scope of the asserted claims, summarized below. We reserve all rights and defenses.

1. Subject Patent — Summary

Summary of U.S. Patent No. 8,685,998

A concise summary of U.S. Patent No. 8,685,998 is provided below, based on a review of the United States Patent and Trademark Office (USPTO) database. A search of the 2026 dockets for the Court of Appeals for the Federal Circuit (CAFC) did not yield any results for this patent.

Title: Tacrolimus for improved treatment of transplant patients.

Assignee: The current assignee of record is Veloxis Pharmaceuticals Inc. The original assignee was Veloxis Pharmaceuticals AS.

Inventors:

- Robert D. Gordon
- Per Holm
- Anne-Marie Lademann
- Tomas Norling

Filing Date: July 7, 2009.

Issue Date: April 1, 2014.

Abstract: The patent describes an extended-release...

4. Litigation History of the Patent

Public records reflect that the 8685998 Patent has been the subject of the following litigation,

which informs our view of the asserted claims and your client's enforcement posture:

• Veloxis Pharmaceuticals AS v. Zydus Cadila et al. — 1:26-cv-00467 · Delaware District Court · filed 2026-04-23 · Open

3. Request

In light of the foregoing, we request that your client (i) provide a detailed claim chart identifying each accused product or service and mapping every limitation of each asserted claim, (ii) identify any prior art known to your client, including any references cited during prosecution or reexamination, and (iii) substantiate the basis for any damages or licensing demand. We are prepared to discuss the matter further once we have received and reviewed the foregoing.

Sincerely,

[Your Name]

DISCLAIMER. This document is a machine-generated sample. The factual assertions, prior-art citations, and legal arguments above are AI-produced and may contain errors, omissions, or outdated information. Do not transmit this letter, in whole or in part, to any party. This is not legal advice; no attorney-client relationship is created by its existence. Consult a licensed patent attorney before responding to any patent-infringement assertion.

Generated May 14, 2026 by ihatepatentrolls.com — sample only.